The evolving field of biodefence: therapeutic developments and diagnostics.
about
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.Design and Synthesis of Aryl Ether Inhibitors of theBacillus AnthracisEnoyl-ACP ReductaseEvaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: Synthesis, crystallography, modeling, kinetic and cellular based studiesStructural basis for the neutralization and specificity of Staphylococcal enterotoxin B against its MHC Class II binding siteStructural basis of affinity maturation and intramolecular cooperativity in a protein-protein interactionEpitope targeting of tertiary protein structure enables target-guided synthesis of a potent in-cell inhibitor of botulinum neurotoxin.Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency.Peptide inhibitors MAP the way towards fighting anthrax pathogenesis.Characterization of a novel high-affinity monoclonal immunoglobulin G antibody against the ricin B subunit.Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.Anthrax edema toxin modulates PKA- and CREB-dependent signaling in two phases.Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity.Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malariaIdentification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen.Botulinum neurotoxin A protease: discovery of natural product exosite inhibitorsSynthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.Identifying chelators for metalloprotein inhibitors using a fragment-based approach.Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entryNeutralising antibodies against ricin toxin.Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening.Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone PharmacophoreIdentification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screeningFighting anthrax with fliesVP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in miceA chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factorEmbryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discoveryMechanistic insights into the neutralization of cytotoxic abrin by the monoclonal antibody D6F10.Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain.Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discoveryDevelopment of a Genus-Specific Antigen Capture ELISA for Orthopoxviruses - Target Selection and Optimized ScreeningSynthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndromeFilovirus-like particles as vaccines and discovery tools.Development of a model for marburgvirus based on severe-combined immunodeficiency mice.Biochemical and structural analysis of an Eis family aminoglycoside acetyltransferase from bacillus anthracis.A neutralizing antibody to the a chain of abrin inhibits abrin toxicity both in vitro and in vivo.Bimodal modulation of the botulinum neurotoxin protein-conducting channelNeutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeatsA monoclonal antibody to an abrin chimera recognizing a unique epitope on abrin A chain confers protection from abrin-induced lethality.
P2860
Q25256700-AA9445E0-3142-44E8-B2A8-F38B2EBFA0DAQ27651378-028CE08B-6AD7-481F-AFBF-9A8119428BABQ27675949-57C13639-A90A-4263-AF8F-C7AF28512D8FQ27681324-C7F87C12-271E-47D7-9FC4-E559042AF1EDQ30352142-6439402E-6D1F-4F36-9E23-17FAF69522C6Q30374260-C811944C-214D-4BF5-9F4C-043AFCFE0282Q30423794-0A02E515-9316-4155-BA8A-403E6F18B7ACQ33236706-BF3B36ED-6C0E-4C53-AE94-4DC3AFA8582CQ33244199-21CD66E6-AB23-4102-BD1F-E5A67619D647Q33334776-C7E8D085-25E6-433D-81D5-4512017EDCBDQ33380169-85D6A707-EB04-452D-B562-8F56AA438B2EQ33476009-49175A6F-CC9F-48E4-9C20-258DDD3E291FQ33654562-373495E8-F50A-487B-BE28-2639A33AB62BQ33655087-5881D972-E3F2-4561-94F4-D104143B17FBQ33703468-71536949-5D17-4FAC-9ED5-B987F73BBCDEQ33739700-9DD2CD27-F6C0-40EB-876D-A52E2FC4E0E9Q33781388-7F9C333C-13B2-40C0-8A92-71557EA881B7Q33785133-64D85E87-8811-4F06-BF7A-E5793B6939FBQ33919740-D5C98BC3-3669-48F6-AD33-0192FB291900Q34068107-E461905B-2301-42D4-BE15-D403F4A4AD7BQ34074218-EBCD6CF0-9B88-4B44-856F-27532AA07288Q34317228-DCFD7C1B-F1AD-4F01-9D23-7282A75B158FQ34355048-FDA1D017-9324-4C94-A26C-0218F0E81E0BQ34480470-A7155C4A-3B80-45AA-9FBD-FF6D9F465211Q34509643-8CCB0B7C-39B1-4015-BFDB-9DF8D87FB8EFQ34665879-361726E5-23BE-403E-AAB0-7D59F2B15206Q34761514-5C7800BF-0D64-4C7D-AAC9-D319A5B29448Q34850583-6AC84F6D-88E8-431F-901C-3B649D5B3BA7Q34906649-37F0AB50-9D2F-4F55-91E0-8303A17EEDA9Q35073984-48D8884B-A304-4D43-9916-D193782452CDQ35772134-74EA950C-2EDF-4F00-AE75-AE69AE2BCC9EQ35941208-31DD6A3C-A886-420D-94A8-9789EC122CDFQ36126966-65FB2801-8096-4D2C-98A9-B4DE8A78DF9AQ36198685-478B93B6-9EF9-4E76-B612-1CCDE85910DAQ36310674-A36F77DE-78CA-42F9-B8D2-B61F2C19353CQ36350988-750D2860-06CF-4F95-9B75-7B8493A8F28FQ36672525-DE6E9B70-F3E7-444D-93D3-67404E1B0B38Q37083575-917EC478-2A9C-48A2-8304-6F1A3484A9A1Q37113758-EA493236-168C-472C-ACB5-238AB52121DEQ37130182-EF289914-15A1-466C-A1A3-413C50D3B246
P2860
The evolving field of biodefence: therapeutic developments and diagnostics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The evolving field of biodefence: therapeutic developments and diagnostics.
@ast
The evolving field of biodefence: therapeutic developments and diagnostics.
@en
type
label
The evolving field of biodefence: therapeutic developments and diagnostics.
@ast
The evolving field of biodefence: therapeutic developments and diagnostics.
@en
prefLabel
The evolving field of biodefence: therapeutic developments and diagnostics.
@ast
The evolving field of biodefence: therapeutic developments and diagnostics.
@en
P2093
P2860
P356
P1476
The evolving field of biodefence: therapeutic developments and diagnostics.
@en
P2093
Alan L Schmaljohn
Erik A Henchal
James C Burnett
P2860
P2888
P304
P356
10.1038/NRD1694
P50
P577
2005-04-01T00:00:00Z
P5875
P6179
1048843121